
OR WAIT null SECS
© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
Innovation in excipients is explicitly needed to meet current drug development demands. They are crucial for addressing challenges in formulation and drug delivery, particularly in optimizing oral solid dosage bioavailability, a main challenge for developers.
The industry is shifting toward rational design using mechanistic models and hypothesis-driven strategies to generate efficient solutions. Excipients are the physical components manipulated in this process to optimize drug delivery.
Excipients are integral to specialty dosage drugs. For instance, 3D-printed tablets are being developed to achieve precise, delayed delivery for specific treatments, which requires highly specialized excipient properties.
Regulatory decisions regarding specific ingredients can have profound impacts. A ban on ingredients, such as the potential titanium dioxide ban, could have significantly crippled pharma products.
Excipient quality affects overall quality assurance/quality control. Strategies for accelerating development and reducing risk require maintaining a flexible CMC process that ensures quality.
Supply chain pressures, including the strategy of achieving a regionalized supply chain, are crucial strategies for optimizing efficiency and affect small molecule development and excipient use in pharma.
The emerging prevalence of digitalization is a key topic for manufacturers handling excipients. Digital transformation and data integrity protocols are crucial strategies for optimizing drug development and manufacturing efficiency.
The industry is focused on mastering AI capabilities and data integration to optimize bio/pharmaceutical manufacturing. Specifically, AI/ML in-silico modeling can accelerate poorly soluble drug development, which often requires specialized excipient strategies (like amorphous solid dispersion development).